This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before using herbs, especially if you are pregnant, nursing, taking medications, or have a medical condition.
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Ligusticum chuanxiong is a traditional Chinese botanical drug renowned for its anti-inflammatory and antioxidant properties, primarily used to treat cardio-cerebral vascular diseases [PMID:40235541].
Background
Ligusticum chuanxiong Hort. (also known as Chuanxiong or Szechwan lovage rhizome) is a perennial Umbelliferae herb whose dried rhizome is used as a medicinal material [PMID:39180449, PMID:39338320]. It is widely used in traditional medicine across Asia, including China, Japan, and Korea [PMID:29486278, PMID:35173614].
Traditional uses
It is used in traditional Chinese medicine to activate blood circulation, remove blood stasis, and treat conditions such as cardio-cerebrovascular diseases, gynecological diseases, stroke, dizziness, and insomnia [PMID:39338320, PMID:39180449, PMID:40505759, PMID:39334868].
Active compounds
The herb contains phthalides (including Z-ligustilide and various butylphthalide derivatives), alkaloids (notably tetramethylpyrazine/ligustrazine and beta-asarone), ferulic acid derivatives, and pectic polysaccharides [PMID:29486278, PMID:35483189, PMID:32135035, PMID:29358153, PMID:35287839, PMID:40490171].
Mechanism of action
Mechanisms include antioxidant and anti-inflammatory activities, suppression of the oxidative stress-apoptosis cycle, vasodilation, neuroprotection, and regulation of the IL-6/STAT3 axis [PMID:40442709, PMID:35483189, PMID:37300676]. Tetramethylpyrazine specifically exhibits anti-apoptosis, angiogenesis regulation, and endothelial protection [PMID:35483189].
Clinical evidence
Evidence CCardio-cerebrovascular diseases
Widely used with reported therapeutic effects on cardiovascular and cerebrovascular diseases [PMID:29486278, PMID:40235541].
Evidence CCerebral ischemia/reperfusion injury
Ligustrazine provides noticeable protection against cerebral ischemia/reperfusion injury [PMID:26109963].
Evidence DOsteoporosis (Animal Model)
Ethanol extract (CXE) improved proliferation and differentiation of osteoblasts and protected ovariectomized hyperlipidemic rats from bone loss [PMID:32138532].
Evidence DAcute Pyelonephritis (Animal Model)
Extract improved renal function and alleviated inflammatory responses via the IL-6/STAT3 axis in E. coli-infected rats [PMID:37300676].
Evidence CAlzheimer's Disease
As part of the Danggui-Shaoyao-San formula, it may alleviate cognitive dysfunction in AD patients [PMID:27493835].
Safety & adverse effects
The herb is reported to have high safety and low side effects [PMID:35173614]. However, the plant tends to accumulate cadmium, which may exceed the limit of 1 mg/kg stipulated by the Chinese Pharmacopoeia (2025 edition) [PMID:42079722].
Evidence summary
The evidence consists primarily of reviews and preclinical animal or in vitro studies (Levels C and D), with a strong focus on the pharmacological activities of its isolated compounds like tetramethylpyrazine.
PubMed sources
1.PMID: 40235541 (2025) — Ligusticum chuanxiong: a chemical, pharmacological and clinical review. · Frontiers in pharmacology
2.PMID: 35483189 (2022) — Tetramethylpyrazine: A review on its mechanisms and functions. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
3.PMID: 35496280 (2022) — Network Pharmacology and Molecular Docking to Elucidate the Potential Mechanism of Ligusticum Chuanxiong Against Osteoarthritis. · Frontiers in pharmacology
4.PMID: 40442709 (2025) — Carbon dots derived from Ligusticum Chuanxiong mitigate cardiac injury by disrupting the harmful oxidative stress-apoptosis cycle. · Journal of nanobiotechnology
No direct government monograph is available for this herb. The content below is AI-generated and has not been verified against an authoritative government source. Use the search links to check official sources before relying on this information.
— A systematic review on the rhizome of Ligusticum chuanxiong Hort. (Chuanxiong).
· Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
6.PMID: 26109963 (2015) — Ligustrazine monomer against cerebral ischemia/reperfusion injury. · Neural regeneration research
7.PMID: 38735486 (2024) — Bibliometric analysis of research progress on tetramethylpyrazine and its effects on ischemia-reperfusion injury. · Pharmacology & therapeutics
8.PMID: 39180449 (2024) — Ligusticum chuanxiong Hort.: a review of its phytochemistry, pharmacology, and toxicology. · The Journal of pharmacy and pharmacology
9.PMID: 32138532 (2020) — Chuanxiong (Rhizome of Ligusticum chuanxiong) Protects Ovariectomized Hyperlipidemic Rats from Bone Loss. · The American journal of Chinese medicine
10.PMID: 39338320 (2024) — Evaluation of the Pharmaceutical Activities of Chuanxiong, a Key Medicinal Material in Traditional Chinese Medicine. · Pharmaceuticals (Basel, Switzerland)
11.PMID: 27493835 (2016) — Danggui-Shaoyao-San: New Hope for Alzheimer's Disease. · Aging and disease
12.PMID: 34351568 (2021) — The Roles of Tetramethylpyrazine During Neurodegenerative Disease. · Neurotoxicity research
13.PMID: 35173614 (2021) — Research Advances in Cardio-Cerebrovascular Diseases of Ligusticum chuanxiong Hort. · Frontiers in pharmacology
14.PMID: 32135035 (2020) — Z-ligustilide: A review of its pharmacokinetics and pharmacology. · Phytotherapy research : PTR
15.PMID: 32054304 (2020) — Effects of Herbal Medicines on Pain Management. · The American journal of Chinese medicine
17.PMID: 26958073 (2016) — Novel phthalide derivatives identified from Ligusticum chuanxiong (Chuanxiong). · Chinese medicine
18.PMID: 32820957 (2020) — Three new compounds from the rhizome of Ligusticum chuanxiong and their anti-inflammation activities. · Journal of Asian natural products research
19.PMID: 40490171 (2025) — Beta-asarone alleviated cerebral ischemia/reperfusion injury by targeting PINK1/Parkin-dependent mitophagy. · European journal of pharmacology
20.PMID: 35287839 (2022) — The isolation, structural features and biological activities of polysaccharide from Ligusticum chuanxiong: A review. · Carbohydrate polymers
22.PMID: 40505759 (2025) — Phthalide extract from stems and leaves of Ligusticum chuanxiong attenuates cerebral I/R injury via CaSR-mediated NLRP3 inflammasome suppression. · Journal of ethnopharmacology
23.PMID: 37300676 (2023) — Szechwan Lovage Rhizome Extract Improves Renal Function and Alleviates Inflammatory Responses in Pyelonephritis Rats Infected with Escherichia Coli via IL-6/STAT3 Axis. · Cellular and molecular biology (Noisy-le-Grand, France)
24.PMID: 35889462 (2022) — Antifungal Effects and Active Components of Ligusticum chuanxiong. · Molecules (Basel, Switzerland)
25.PMID: 25206882 (2014) — Houshiheisan compound prescription protects neurovascular units after cerebral ischemia. · Neural regeneration research
26.PMID: 39334868 (2024) — Sedative-Hypnotic Effect and Mechanism of Carbon Nanofiber Loaded with Essential Oils of Ligusticum chuanxiong (Ligusticum chuanxiong Hort.) and Finger Citron (Citrus medica L. var. sarcodactylis) on Mice Models of Insomnia. · Biomolecules
27.PMID: 41088207 (2025) — A novel ligustrazine-based nanodelivery system protects against doxorubicin-induced cardiotoxicity by targeting the SIRT5-DUSP1 axis for mitochondrial repair. · Journal of nanobiotechnology